# OnCo record paper-stecklein-ctdna-rcb-tnbc-residual-disease-npj-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-stecklein-ctdna-rcb-tnbc-residual-disease-npj-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-stecklein-ctdna-rcb-tnbc-residual-disease-npj-2023" ;
  schema:name "ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease"@en ;
  schema:description "Among 80 women with triple-negative cancer left at surgery after chemotherapy, a third had ctDNA in their blood; their three-year event-free survival was 48% against 82%, and the blood test added to the pathologist's residual cancer burden score."@en ;
  schema:url <https://onco.cc/key-papers/paper-stecklein-ctdna-rcb-tnbc-residual-disease-npj-2023/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1038/s41523-023-00512-7>, <https://pubmed.ncbi.nlm.nih.gov/36878909/> ;
  schema:sameAs <https://doi.org/10.1038/s41523-023-00512-7> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Stecklein SR, Kimler BF, Yoder R, et al." ;
  onco:related <https://onco.cc/biomarkers/ctdna-mrd-positive/> ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-early/> ;
  onco:technologies <https://onco.cc/technologies/mrd-testing/> ;
  onco:terms <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/rcb/>, <https://onco.cc/terms/mrd/> ;
  onco:people <https://onco.cc/people/priyanka-sharma/> .